{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T09:39:12Z","timestamp":1782812352713,"version":"3.54.5"},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004028","name":"Jiangnan University","doi-asserted-by":"publisher","award":["YXXK2024092602"],"award-info":[{"award-number":["YXXK2024092602"]}],"id":[{"id":"10.13039\/501100004028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004028","name":"Jiangnan University","doi-asserted-by":"publisher","award":["YXXK2024092612"],"award-info":[{"award-number":["YXXK2024092612"]}],"id":[{"id":"10.13039\/501100004028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202910"],"award-info":[{"award-number":["82202910"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81603158"],"award-info":[{"award-number":["81603158"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013114","name":"Yunnan Key Research and Development Program","doi-asserted-by":"publisher","award":["202402AA310032"],"award-info":[{"award-number":["202402AA310032"]}],"id":[{"id":"10.13039\/501100013114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["JUSRP123072"],"award-info":[{"award-number":["JUSRP123072"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.apsb.2025.04.030","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T19:45:19Z","timestamp":1746474319000},"page":"3646-3662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Discovery of Yersinia LcrV as a novel biased agonist of formyl peptide receptor 1 to bi-directionally modulate intracellular kinases in triple-negative breast cancer"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-2281","authenticated-orcid":false,"given":"Yunjun","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.04.030_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.04.030_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc2069","article-title":"G-protein-coupled receptors and cancer","volume":"7","author":"Dorsam","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2025.04.030_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrd3320","article-title":"G protein-coupled receptors: novel targets for drug discovery in cancer","volume":"10","author":"Lappano","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.04.030_bib4","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1021\/acs.jmedchem.8b00435","article-title":"Biased Ligands of G Protein-coupled receptors (GPCRs): structure\u2013functional selectivity relationships (SFSRs) and therapeutic potential","volume":"61","author":"Tan","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.04.030_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","article-title":"Biased allosteric modulators: new frontiers in GPCR drug discovery","volume":"42","author":"Slosky","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2025.04.030_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1158\/0008-5472.CAN-20-1662","article-title":"Inhibition of G protein-coupled receptor kinase 2 promotes unbiased downregulation of IGF1 receptor and restrains malignant cell growth","volume":"81","author":"Crudden","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/en.2018-00843","article-title":"PI3K\u03b2\u2014a versatile transducer for GPCR, RTK, and small GTPase signaling","volume":"160","author":"Bresnick","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2025.04.030_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nature14243","article-title":"Pathogen-secreted proteases activate a novel plant immune pathway","volume":"521","author":"Cheng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.04.030_bib9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.18632\/aging.202246","article-title":"\u03b2-Arrestin-2 attenuates hepatic ischemia-reperfusion injury by activating PI3K\/Akt signaling","volume":"13","author":"Chen","year":"2021","journal-title":"Aging-Us"},{"key":"10.1016\/j.apsb.2025.04.030_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib11","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/jcb.27451","article-title":"MAPK\/ERK pathway inhibition is a promising treatment target for adrenocortical tumors","volume":"120","author":"Pereira","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2025.04.030_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.apsb.2025.04.030_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2025.04.030_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2025.04.030_bib15","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.2147\/CMAR.S182795","article-title":"FPR1 mediates the tumorigenicity of human cervical cancer cells","volume":"10","author":"Cao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1096\/fj.09-154096","article-title":"Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2","volume":"25","author":"Khau","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2025.04.030_bib17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41388-023-02919-9","article-title":"A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo","volume":"43","author":"Al-Ali","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.04.030_bib18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bbamcr.2018.06.010","article-title":"Inhibition of the AnxA1\/FPR1 autocrine axis reduces MDA-MB-231 breast cancer cell growth and aggressiveness in vitro and in vivo","volume":"1865","author":"Vecchi","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74350-z","article-title":"Application of small molecule FPR1 antagonists in the treatment of cancers","volume":"10","author":"Ahmet","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.04.030_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/pr.109.001578","article-title":"International union of basic and clinical pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family","volume":"61","author":"Ye","year":"2009","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.apsb.2025.04.030_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/molecules22030455","article-title":"The formyl peptide receptors: diversity of ligands and mechanism for recognition","volume":"22","author":"He","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.04.030_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.04.030_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105117","article-title":"Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling","volume":"161","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib24","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1096\/fj.201903206R","article-title":"Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity","volume":"34","author":"Ge","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2025.04.030_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41435-019-0065-0","article-title":"Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics","volume":"20","author":"Demeure","year":"2019","journal-title":"Gene Immun"},{"key":"10.1016\/j.apsb.2025.04.030_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00646-17","article-title":"Glutathionylation of Yersinia pestis LcrV and its effects on plague pathogenesis","volume":"8","author":"Mitchell","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.04.030_bib27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1118476","article-title":"The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles","volume":"310","author":"Mueller","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.04.030_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41586-019-1570-z","article-title":"FPR1 is the plague receptor on host immune cells","volume":"574","author":"Osei-Owusu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.04.030_bib29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.chom.2008.09.004","article-title":"Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis","volume":"4","author":"Depaolo","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.apsb.2025.04.030_bib30","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1128\/IAI.73.8.5152-5159.2005","article-title":"LcrV plague vaccine with altered immunomodulatory properties","volume":"73","author":"Overheim","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.apsb.2025.04.030_bib31","article-title":"Agonist concentration-dependent changes in FPR1 conformation lead to biased signaling for selective activation of phagocyte functions","volume":"119","author":"Wang","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.04.030_bib32","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cell.2019.04.044","article-title":"Illuminating G-protein-coupling selectivity of GPCRs","volume":"177","author":"Inoue","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.04.030_bib33","article-title":"Cryo-EM structure of the human chemerin receptor 1-Gi protein complex bound to the C-terminal nonapeptide of chemerin","volume":"120","author":"Wang","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.04.030_bib34","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2020.06.020","article-title":"Revealing the activity of trimeric G-proteins in live cells with a versatile biosensor design","volume":"182","author":"Maziarz","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.04.030_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40537-023-00844-y","article-title":"BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors","volume":"10","author":"Liu","year":"2023","journal-title":"J Big Data"},{"key":"10.1016\/j.apsb.2025.04.030_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.apsb.2025.04.030_bib38","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41596-022-00709-3","article-title":"The cell-line-derived subcutaneous tumor model in preclinical cancer research","volume":"17","author":"Stribbling","year":"2022","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2025.04.030_bib39","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41401-020-00523-1","article-title":"Anti-inflammatory signaling through G protein-coupled receptors","volume":"41","author":"Ge","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.04.030_bib40","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.04.030_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-20-0465","article-title":"A TLR3 Ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency","volume":"11","author":"Le Naour","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2025.04.030_bib42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41388-019-0997-x","article-title":"SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K\/AKT\/SOX2 axis and beyond","volume":"39","author":"Schaefer","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.04.030_bib43","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1073\/pnas.0905657107","article-title":"Stk40 links the pluripotency factor Oct4 to the Erk\/MAPK pathway and controls extraembryonic endoderm differentiation","volume":"107","author":"Li","year":"2010","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.apsb.2025.04.030_bib44","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.apsb.2023.05.005","article-title":"Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.04.030_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/aps.2011.183","article-title":"GPCRs and cancer","volume":"33","author":"Lappano","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.04.030_bib46","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/0008-5472.CAN-17-1089","article-title":"The CARMA3\u2013Bcl10\u2013MALT1 signalosome drives NF\u03baB activation and promotes aggressiveness in angiotensin II receptor\u2013positive breast cancer","volume":"78","author":"Ekambaram","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/0008-5472.CAN-18-1745","article-title":"Membrane-anchored serine proteases and protease-activated receptor-2\u2013mediated signaling: co-conspirators in cancer progression","volume":"79","author":"Pawar","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.04.030_bib48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/379557a0","article-title":"Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors","volume":"379","author":"Daub","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.04.030_bib49","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2741\/2805","article-title":"Crosstalk between G-protein-coupled receptors and Epidermal growth factor receptor in cancer","volume":"13","author":"Bhola","year":"2008","journal-title":"Front Biosci-Landmrk"},{"key":"10.1016\/j.apsb.2025.04.030_bib50","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1074\/jbc.R114.613414","article-title":"GIV\/Girdin transmits signals from multiple receptors by triggering trimeric G protein activation","volume":"290","author":"Garcia-Marcos","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.04.030_bib51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.mce.2015.04.017","article-title":"Estrogen receptor alpha-36 (ER-\u03b136): a new player in human breast cancer","volume":"418","author":"Wang","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.apsb.2025.04.030_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2227510","article-title":"A chemically defined TLR3 agonist with anticancer activity","volume":"12","author":"Le Naour","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.apsb.2025.04.030_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216635","article-title":"A novel antagonist of the CCL5\/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation","volume":"583","author":"Chen","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2025.04.030_bib54","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-020-2569-1","article-title":"Structural basis of GPBAR activation and bile acid recognition","volume":"587","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.04.030_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117054119","article-title":"Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity","volume":"119","author":"Ma","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.apsb.2025.04.030_bib56","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2013.11.019","article-title":"p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents","volume":"344","author":"Sui","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2025.04.030_bib57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS\u2013RAF\u2013MEK\u2013ERK signaling pathway in human cancer: current status in clinical trials","volume":"10","author":"Song","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.apsb.2025.04.030_bib58","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41467-023-42257-8","article-title":"USP36 stabilizes nucleolar Snail1 to promote ribosome biogenesis and cancer cell survival upon ribotoxic stress","volume":"14","author":"Qin","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.04.030_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100815","article-title":"Suppression of tumor progression by thioredoxin-interacting protein-dependent adenosine 2B receptor degradation in a PLAG-treated Lewis lung carcinoma-1 model of non\u2013small cell lung cancer","volume":"31","author":"Kim","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.apsb.2025.04.030_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7150\/ijbs.22896","article-title":"The role of G protein-coupled receptor kinases in cancer","volume":"14","author":"Yu","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2025.04.030_bib61","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2007.06.018","article-title":"Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein","volume":"133","author":"Foligne","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2025.04.030_bib62","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.4049\/jimmunol.1800985","article-title":"A combined YopB and LcrV subunit vaccine elicits protective immunity against Yersinia infection in adult and infant mice","volume":"202","author":"Heine","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.04.030_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03223-21","article-title":"Combinatorial viral vector-based and live attenuated vaccines without an adjuvant to generate broader immune responses to effectively combat pneumonic plague","volume":"12","author":"Kilgore","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.04.030_bib64","doi-asserted-by":"crossref","first-page":"16077","DOI":"10.1073\/pnas.2536719100","article-title":"Gi protein activation in intact cells involves subunit rearrangement rather than dissociation","volume":"100","author":"Bunemann","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.apsb.2025.04.030_bib65","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213140120","article-title":"Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer","volume":"120","author":"Zhao","year":"2023","journal-title":"P Natl Acad Sci USA"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525002977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525002977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:16:32Z","timestamp":1762604192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525002977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2211383525002977"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.04.030","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of Yersinia LcrV as a novel biased agonist of formyl peptide receptor 1 to bi-directionally modulate intracellular kinases in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}